Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25308-25319

  Yuan, Kaiyu ^a   Yong, Sun ^a   Xu, Fei ^a   Zhou, Tong ^b   McDonald, Jay M ^a,c   Chen, Yabing ^a,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Calmodulin antagonists; Death receptor 5; Pancreatic cancer; Resistance

Indexed keywords

CASPASE 3; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 5; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN TYROSINE KINASE; TAMOXIFEN; TIGATUZUMAB; TRIFLUOPERAZINE; ANTINEOPLASTIC AGENT; CALMODULIN; CASP8 PROTEIN, HUMAN; CASPASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN BINDING; SP1 PROTEIN, HUMAN; TRA-8 MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; CONTROLLED STUDY; DR5 GENE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CALMODULIN; CASPASE 8; CASPASE INHIBITORS; CELL LINE, TUMOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MALE; MICE, NUDE; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; SRC-FAMILY KINASES; TAMOXIFEN; TIME FACTORS; TRANSFECTION; TRIFLUOPERAZINE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944446459     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4490     Document Type: Article

References (50)

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nature reviews Gastroenterology and hepatology. 2009; 6:699-708.
2. Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Archives of pathology and laboratory medicine. 2012; 136:100-109.
3. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP. 2007; 8:545-552.
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. Groupe Tumeurs Digestives of U, Intergroup P. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine. 2011; 364:1817-1825.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
6. Schutze S, Tchikov V, Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nature reviews Molecular cell biology. 2008; 9:655-662.
7. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006; 25:4798-4811.
8. Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Experimental cell research. 2010; 316:887-899.
9. Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets. 2008; 8:124-131.
10. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. European journal of pharmacology. 2009; 625:63-72.
11. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clinical cancer research. 2010; 16:5883-5891.
12. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Praga S, Percent I, Saleh M. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer biotherapy and radiopharmaceuticals. 2010; 25:13-19.
13. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clinical cancer research. 2010; 16:1701-1708.
14. Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra SK, Picha KS, Pour PM. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAILresistant human pancreatic cancer cells. Clinical cancer research. 2001; 7:407-414.
15. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature immunology. 2009; 10:348-355.
16. Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell death and differentiation. 2013; 20:858-868.
17. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosisinducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas. 2001; 23:251-258.
18. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H, Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene. 2000; 19:5477-5486.
19. Yuan K, Jing G, Chen J, Liu H, Zhang K, Li Y, Wu H, McDonald JM, Chen Y. Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). J Biol Chem. 2011; 286:24776-24784.
20. Jing G, Yuan K, Turk AN, Jhala NC, Arnoletti JP, Zhang K, McDonald JM, Chen Y. Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis. Laboratory investigation. 2011; 91:896-904.
21. Pawar P, Ma L, Byon CH, Liu H, Ahn EY, Jhala N, Arnoletti JP, McDonald JM, Chen Y. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clinical cancer research. 2009; 15:1288-1296.
22. Pawar PS, Micoli KJ, Ding H, Cook WJ, Kappes JC, Chen Y, McDonald JM. Calmodulin binding to cellular FLICE-like inhibitory protein modulates Fas-induced signalling. The Biochemical journal. 2008; 412:459-468.
23. Chen Y, Pawar P, Jhala N, McDonald JM. Regulators of apoptosis in cholangiocarcinoma. Hyperplastic and Neoplastic Growth of Cholangiocytes. Research Signpost Publications, India. 2008.
24. Chin D, Means AR. Calmodulin: a prototypical calcium sensor. Trends in cell biology. 2000; 10:322-328.
25. Chen QY, Wu LJ, Wu YQ, Lu GH, Jiang ZY, Zhan JW, Jie Y, Zhou JY. Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines. Molecular medicine reports. 2009; 2:811-817.
26. Frankfurt OS, Sugarbaker EV, Robb JA, Villa L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer letters. 1995; 97:149-154.
27. Yuan K, Sun Y, Zhou T, McDonald J, Chen Y. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clinical cancer research. 2013; 19:4750-4759.
28. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 2001; 507:381-385.
29. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Molecular cancer therapeutics. 2012; 11:3-13.
30. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clinical cancer research. 2007; 13:6187-6194.
31. Dietze EC, Caldwell LE, Grupin SL, Mancini M, Seewaldt VL. Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization. The Journal of biological chemistry. 2001; 276:5384-5394.
32. Chen Y, Pawar P, Pan G, Ma L, Liu H, McDonald JM. Calmodulin binding to the Fas-mediated death-inducing signaling complex in cholangiocarcinoma cells. Journal of cellular biochemistry. 2008; 103:788-799.
33. Ahn EY, Lim ST, Cook WJ, McDonald JM. Calmodulin binding to the Fas death domain. Regulation by Fas activation. The Journal of biological chemistry. 2004; 279:5661-5666.
34. Cursi S, Rufini A, Stagni V, Condo I, Matafora V, Bachi A, Bonifazi AP, Coppola L, Superti-Furga G, Testi R, Barila D. Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006; 25:1895-1905.
35. De Toni EN, Kuntzen C, Gerbes AL, Thasler WE, Sonuc N, Mucha SR, Camaj P, Bruns C, Goke B, Eichhorst ST. P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes. Journal of hepatology. 2007; 46:682-691.
36. Ozawa F, Friess H, Kleeff J, Xu ZW, Zimmermann A, Sheikh MS, Buchler MW. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer letters. 2001; 163:71-81.
37. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer research. 1999; 59:734-741.
38. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer research. 2005; 65:2344-2352.
39. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. The Prostate. 2004; 61:35-49.
40. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer research. 2004; 64:2580-2589.
41. Kim YH, Park JW, Lee JY, Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis. 2004; 25:1813-1820.
42. Lin T, Chen Y, Ding Z, Luo G, Liu J, Shen J. Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway. PloS one. 2013; 8:e63966.
43. Sun M, Zhang J, Liu S, Liu Y, Zheng D. Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. Oncology reports. 2008; 19:177-185.
44. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol. 2001; 3:409-416.
45. Do MT, Na M, Kim HG, Khanal T, Choi JH, Jin SW, Oh SH, Hwang IH, Chung YC, Kim HS, Jeong TC, Jeong HG. Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPKCHOP signaling pathways. Food and chemical toxicology. 2014; 71:51-59.
46. Portanova P, Notaro A, Pellerito O, Sabella S, Giuliano M, Calvaruso G. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. International journal of oncology. 2013; 43:121-130.
47. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Journal of immunology. 2008; 180:6199-6210.
48. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature medicine. 2001; 7:954-960.
49. Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri FR, Sun SY. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAILinduced apoptosis in human lung cancer cells. Cancer research. 2007; 67:4973-4980.
50. Heath JM, Sun Y, Yuan K, Bradley WE, Litovsky S, Dell'italia LJ, Chatham JC, Wu H, Chen Y. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitu